ER-positive
Estrogen receptor
Tumor cells show estrogen-receptor expression on pathology testing.
Breast Cancer Subtype · ER-Positive · PR-Positive
Hormone-Positive Breast Cancer Treatment: ER, PR and Endocrine Pathways
Hormone receptor-positive breast cancer includes tumors driven by estrogen and/or progesterone signaling. Treatment depends on stage, menopausal status, recurrence risk, HER2 status and molecular changes that can emerge over time.
Answer first: Endocrine therapy is often central to hormone-sensitive breast cancer. Targeted medicines, chemotherapy, surgery and radiation may also be used according to stage, risk and resistance pathways.
Cancer Consultation
Speak With Our Cancer Patient Care Team
Tell us where you are in your cancer journey. Our Patient Care Team can answer questions and help determine the next step.
*
Required fields
Prefer to speak with someone now?
1-800-923-7878
✓
Stage 4 & advanced cancer patients welcome
✓
Out-of-state & international patients welcome
✓
Questions before scheduling are welcome
What ER-positive and PR-positive mean
Hormone receptors describe a treatment-relevant vulnerability.
PR-positive
Progesterone receptor
PR adds information about hormone signaling but is interpreted with ER, HER2 and the full pathology report.
HER2 status
A second pathway
HR-positive/HER2-negative and HR-positive/HER2-positive cancers have different treatment choices.
Hormone-sensitive treatment protocols
Examples used across early, recurrent and metastatic settings.
Endocrine medicines
Tamoxifen (Nolvadex), anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) and fulvestrant (Faslodex) may be used according to menopausal status and treatment setting. Ovarian suppression may be part of care for selected premenopausal patients.
Targeted combinations
Ribociclib (Kisqali), palbociclib (Ibrance) and abemaciclib (Verzenio) are CDK4/6 inhibitors used in defined settings. Mutation-directed options may include alpelisib (Piqray), capivasertib (Truqap), elacestrant (Orserdu) or a PARP inhibitor when the relevant biomarker and indication are present.
When chemotherapy enters the plan
Chemotherapy may be considered for higher-risk early disease, rapidly progressive metastatic disease, endocrine-resistant disease or a visceral crisis. The exact drugs depend on prior care and present health.
Testing after progression
Resistance can create new actionable information.
- Reconfirm ER, PR and HER2 on recurrent tissue when possible.
- Evaluate ESR1, PIK3CA, AKT1, PTEN and other alterations when relevant to a treatment decision.
- Consider germline BRCA1, BRCA2 or PALB2 testing based on history and current guidelines.
- Use imaging and clinical tempo—not a single laboratory marker—to understand progression.
Natural and integrative support
Support the person through long-duration therapy.
Metabolic health
Nutrition, movement and body composition
A sustainable program may address insulin resistance, strength, bone health, cardiovascular health and energy.
Symptom support
Joint pain, sleep and menopausal symptoms
Acupuncture, exercise, mind-body care and individualized natural strategies may support quality of life.
Research review
Polyphenols and botanicals
Curcumin, resveratrol, silymarin, EGCG and mistletoe are evaluated by formulation, evidence level and the patient’s treatment context.
Questions patients ask
Hormone-positive breast cancer FAQs
Are ER-positive and hormone-positive the same?
ER-positive breast cancer is hormone receptor-positive. A tumor may be ER-positive, PR-positive or both.
Does hormone-positive breast cancer always respond to endocrine therapy?
Many tumors respond, but sensitivity and duration vary. Molecular changes can contribute to resistance.
Can integrative care support long-term endocrine treatment?
Yes. A personalized plan may address joint symptoms, sleep, bone and cardiovascular health, energy, nutrition and emotional well-being.
A closer look
How this topic fits the complete breast-cancer plan.
Hormone receptor-positive disease may require years of decision-making rather than one short treatment episode. Menopausal status, bone density, cardiovascular risk, metabolic health, fertility goals, joint symptoms and prior endocrine exposure can all affect the plan. In advanced disease, molecular changes such as ESR1, PIK3CA, AKT1 or PTEN alterations may help explain resistance and open a different pathway.
Integrative care can be especially valuable when long-duration therapy affects daily life. A personalized program may focus on maintaining lean muscle, supporting bone and cardiovascular health, improving sleep, addressing hot flashes or joint discomfort, and protecting the routines that help a patient remain active. The objective is not simply to add supplements; it is to build a sustainable whole-person strategy around the current cancer plan.
Prepare for a Sunridge review
The right records make the first conversation more useful.
Before contacting the Patient Care Team, gather ER and PR percentages, HER2 results, menopausal status, endocrine history, bone-density information, genomic tests and current symptoms. A concise one-page chronology is often helpful: diagnosis date, stage, major test results, treatments received, response, side effects and the questions that matter most now.
Step 1
Send the records
The team can explain which reports and images are needed before a physician review.
Step 2
Define the priorities
List the treatment, symptom, recovery and quality-of-life questions you want the consultation to address.
Step 3
Plan the visit
Out-of-state and international patients can discuss timing, Scottsdale travel and which services require an in-person appointment.
Continue exploring
Explore Sunridge integrative therapies
Learn how these physician-directed therapies are evaluated within a personalized cancer-care program.
A personalized next step
Bring the complete breast-cancer story to the conversation.
Our Patient Care Team can explain which records to send, how a physician review works and what to expect when traveling to Scottsdale.
Request a consultationCall 1-800-923-7878This page is educational and does not provide a diagnosis or individualized treatment recommendation. Medication and integrative-treatment decisions require review of the complete case by qualified clinicians. Content reviewed August 2026.